STOCKHOLM, May 8, 2020 /PRNewswire/ -- The Annual General
Meeting (AGM) of Immunovia AB (publ), corporate identity number
556730-4299 was held in The Spark at Medicon Village, Scheeletorget
1, Lund on May 7, 2020. A summary of the Meeting's
resolutions follows:
Appropriation of the company's profit and loss
The Meeting resolved that available funds of
SEK 335,905,705 be transferred to a
new account and that no dividend is paid.
Directors' and audit fees
The Meeting resolved that Board members should be compensated
with SEK 150,000 for Directors and
SEK 400,000 for the Chairman of the
Board. The Chairman of the Audit Committee and Remuneration
Committee were compensated with SEK
40,000, and other members of these Committees were
compensated with SEK 20,000. Travel
expenses will be reimbursed in accordance with the company's
policy. In addition, it was decided that the auditor should
be paid according to approved invoice.
Election of the Board of Directors, Chairman of the Board and
auditors
The Meeting resolved to re-elect the Directors Carl Borrebaeck, Ann-Christine Sundell, Hans Johansson, Mimmi
Ekberg and Christofer Sjögren as Directors, elect Peter
Høngaard Andersen as new Director, and to re-elect Carl Borrebaeck
as Chairman of the Board. The Meeting elected authorized auditor
Mats-Åke Andersson as the company's auditor, with authorized public
accountant Martin Gustafsson as
deputy auditor.
Guidelines for remunerating senior executives
The Meeting resolved to adopt guidelines for remunerating senior
executives based on a proposal that the Board produced after
recommendation from the Remuneration Committee.
Resolution to authorize the Board to take decisions on new
share issues
The Meeting resolved to authorize the Board to decide on the new
issue of an aggregate maximum number of shares that would mean a
maximum increase of the share capital of twenty (20) percent based
on the aggregate share capital of the company at the time of the
AGM 2020, in accordance with, or departing from, shareholders'
preferential rights, and with or without a decision on contribution
in kind.
Immunovia AB (publ)
The Board of Directors
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q3
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
Questions should be addressed to:
Julie Silber
Director of Investor Relations
Email: julie.silber@immunovia.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia---report-from-agm,c3107447
The following files are available for download:
https://mb.cision.com/Main/13121/3107447/1244517.pdf
|
Release
|